SAHPRA signs MoU with Medicines Control Authority of Zimbabwe
Pretoria, 12 January 2024 – The South African Health Products Regulatory Authority (SAHPRA) has sign...
12 January, 24Looking for a 168澳洲10官网历史开奖记录 官网彩票平台 开奖直播 开奖计划 正规官网开奖 开奖号码结果 澳洲10彩网 – search here:
Pretoria, 12 January 2024 – The South African Health Products Regulatory Authority (SAHPRA) has sign...
12 January, 242024 | Embracing new partnerships and overcoming challenges As we begin 2024, I take this opportunit...
04 January, 24Pretoria, 19 December 2023 – The South African Health Products Regulatory Authority (SAHPRA) is awar...
20 December, 23Pretoria, 14 December 2023 -The South Africa Health Products Regulatory Authority (SAHPRA), in colla...
14 December, 23There have been several cases around the world in which Tranexamic acid has been administered intrat...
21 December, 23The South African Health Products Regulatory Authority (SAHPRA) would like to inform you of a signal...
19 October, 21In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Roche Product...
10 November, 20SAHPRA alerts all healthcare professionals about the risk of serious heart problems, seizures, coma ...
01 November, 20Following 开奖结果查询官网直播 正规官网开奖记录 开奖官网直播2024 开奖官方2024结果 results that indicated levels of increased N-nitroso-varenicline that exceed the Acceptable Daily Intake (ADI) threshold of 733 ng/day calculated by Pfizer, based on ICH M7 guidance, Pfizer Laboratories (Pty) Ltd in South Africa took the decision to initiate a voluntary recall on Champix, batch 18069 and notified SAHPRA Regulatory Compliance Units. Recall process: Recall letter distributed to all healthcare professionals via medpages.
The products are being recalled due to quality defect: the presence of a mutagenic impurity above the threshold limit observed during analysis, as requested by the European Directorate for the Quality of Medicines and Healthcare (EDQM) on new Azido impurities [the presence of Azido (5-AMBBT) mutagesic impurity beyond total threshold limit was observed during analysis].
The products are being recalled due to quality defect: the tablet description should be cross-scored, but instead the tablet has only a single score.